Adolor Corporation has received notification from the Consumer Healthcare Division of GlaxoSmithKline plc that it discontinued development of ADL 2-1294. The companies entered into a development agreement for the compound in 1999.

A Phase 2, proof of concept, double-blind and placebo-controlled clinical trial for eczema itch did not demonstrate a statistically significant difference between the drug and placebo groups. As a consequence, the rights to ADL 2-1294 will revert to Adolor. These results will have no impact on Adolor's plans to seek another partner or to develop ADL 2-1294 for other pain indications.

Santen Pharmaceutical Co. Limited, Japan will continue developing ADL 2-1294 for the treatment of ophthalmic pain. Adolor and Santen entered into a separate development and licensing agreement for the topical uses of ADL 2-1294 for the treatment of ophthalmic pain in April 2000.